Telbivudine comparative studies

Comparative studies A meta-analysis was performed comparing early antiviral efficacy and safety of telbivudine and entecavir in the treatment of patients with hepatitis B e antigen positive chronic hepatitis [106 ]. Six randomised controlled trials involving 555 patients were included and demonstrated that telbivudine was associated with higher rates of HBeAg disappearance and HBeAg seroconversion than entecavir but had higher adverse events (RR 2.11). No specific details of adverse events were illustrated as pooled risk ratios were used. 

Liang J, Jiang MJ, Deng X, Xiao Zhou X. Efficacy and safety of telbivudine compared to Entecavir among HBeAg+ chronic hepatitis B patients a meta-analysis study. Hepat Mon 2013 13(6) e7862. 

In a study in healthy subjects the concurrent use of telbivudine 600 mg daily and adefovir 10 mg daily for 7 days did not alter the pharmacokinetics of either drug, when compared to their use alone. No dosage adjustments of either drug are anticipated to be needed if they are used together. 

In a study in healthy subjects, when a single 600-mg dose of telbivudine was given immediately after a high-fat/high-calorie meal there was no effect on the pharmacokinetics of telbivudine, when compared with the fasting state. Telbivudine may be taken with or without food. 

---